On Friday, uniQure N.V. (NASDAQ:QURE)’s shares declined -7.63% to $28.44, while its weekly performance remained better, showing an upward trend up to 24.41%.
uniQure, declared the pricing of its follow-on public offering of 3,000,000 ordinary shares at price to the public of $29.50 per ordinary share. After deducting the underwriting discounts and other estimated offering expenses payable by uniQure, the net proceeds of the follow-on public offering are predictable to be about $82.4 million (EURO76.5 million). In addition, uniQure has granted the underwriters a 30-day option to purchase up to an additional 450,000 ordinary shares from uniQure at the public offering price, less underwriting discounts. The offering is predictable to close on or about April 15, 2015.
Leerink Partners LLC, Cowen and Company, LLC, and Piper Jaffray & Co. are acting as the joint book-running managers for the offering. Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC, are acting as co-managers.
uniQure N.V., a biopharmaceutical company, develops adeno-associated virus (AAV) based gene therapies through its technology platform for multiple therapeutic areas. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency.
Noah Holdings Limited (NYSE:NOAH)’s shares gained 0.24% to $29.50, during the last trading session on Friday, hitting its highest level, while its weekly performance remained better, showing an upward trend up to 23.28%.
Formerly on March 19, a leading wealth administration service provider with a focus on global wealth investment and asset allocation services for high net worth individuals and enterprises in China, declared that Sequoia Capital China, a leading venture capital firm in China, has made a planned investment in EJ Wealth Administration, Inc., Noah’s majority-owned partner dedicated to internet finance.
Yijie operates “Yuan Gong Bao,” an internet finance platform that provides financial products and services to white-collar professionals in China. As of the end of 2014, Yuan Gong Bao had established cooperative relationships with 205 leading domestic and multinational enterprises in China and achieved cumulative online sales of RMB1.4 billion, representing a 32% compound monthly growth rate since its launch in June 2014.
Noah plans to expand the Yuan Gong Bao internet finance platform to support a range of additional financial products and services counting money market funds, insurance, credit loans, and asset allocation advisory.
Noah Holdings Limited, through its auxiliaries, operates as a wealth administration service provider with focus on distributing wealth administration products in the People’s Republic of China. The company’s products comprise fixed revenue products, counting asset administration plans sponsored by mutual fund administration or securities companies, real estate funds managed by it, and collateralized fixed revenue products sponsored by trust companies that provide investors with fixed rates of return.
At the end of Friday’s trade, BIND Therapeutics, Inc. (NASDAQ:BIND)’s shares gained 5.01% to $6.71, while its weekly performance remained Best, showing an upward trend up to 21.56%.
Formerly on April 2, a clinical-stage nanomedicine platform company, declared an extension of the terms of its global partnership with Pfizer Inc. to create Accurins that optimize the therapeutic potential of two molecularly targeted oncology drugs in Pfizer’s pipeline. The partnershipwas originally established in April 2013 and the timeline for Pfizer to exercise its option to attain the exclusive license for the first program continues to be September 2015. Both companies agreed to an extension of the timeline for the second program through March 2016.
A development milestone was achieved for the first program in December 2014. The 2015 option target date on the first compound remains unchanged and this extension allows BIND and Pfizer an additional year to complete preclinical research evaluating the second program.
Under terms of the original contract, Pfizer has the exclusive option to pursue development and commercialization of the Accurins selected. Both companies will work together on preclinical research, and if Pfizer exercises its option, Pfizer will have responsibility for development and commercialization of the selected Accurins.
BIND received an upfront payment of $4.0 million in 2013, a $1.0 million preclinical development milestone in December 2014, and has the potential to receive payments up to $88.5 million upon the achievement of additional specified development and regulatory events. BIND may also receive additional payments up to $110 million for specified commercial events in addition to royalties in the low single to high single digit percentages on potential future sales of each Accurin commercialized, if any.
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company, develops various targeted and programmable therapeutics. It is developing Accurins that are designed with specific pharmaceutical characteristics intended to target tumors at tissue, cellular, and molecular levels and to result in superior patient outcomes by enhancing the concentration and duration of therapeutic payloads at disease sites while reducing exposure to healthy tissue.
Perrigo Company Public Limited Company (NYSE:PRGO), ended its Friday’s trading session with -0.08% loss, and closed at $198.55, while its weekly performance remained better, showing an upward trend up to 21.27%.
Perrigo Company plc, noted the declaration made by Mylan NV (MYL). Perrigo confirms that it has received an unsolicited, indicative proposal from Mylan regarding a possible offer for the Company.
The Board of Perrigo will meet to talk about the Proposal and a further declaration will be made when appropriate.
There can be no certainty that any offer will be made.
Perrigo Company plc, through its auxiliaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
